Richard A. Larson to Staurosporine
This is a "connection" page, showing publications Richard A. Larson has written about Staurosporine.
Connection Strength
2.039
-
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia. 2021 09; 35(9):2539-2551.
Score: 0.791
-
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. N Engl J Med. 2017 11 09; 377(19):1903.
Score: 0.629
-
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021 06 03; 137(22):3093-3104.
Score: 0.201
-
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018 02 27; 2(4):444-453.
Score: 0.161
-
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 08 03; 377(5):454-464.
Score: 0.153
-
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022 09 27; 6(18):5345-5355.
Score: 0.055
-
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020 10 13; 4(19):4945-4954.
Score: 0.048